Improvement in Tardive Dyskinesia with Aripiprazole Use

Witschy, J. K.; Winter, Andreas

doi:10.1177/070674370505000321

Cited by 26 publications

(9 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our patient TD was covert–that is, it emerged with withdrawal of treatment but persisted indefinitely thereafter. We note with interest the reports of successful treatment of TD with APZ 12 – 14. It has been suggested that these cases can be accounted for by APZ partial agonism at 5-HT 1A receptors 12.…”

Section: Discussionmentioning

confidence: 92%

Motor worsening and tardive dyskinesia with aripiprazole in Lewy body dementia

Boylan

Hirsch²

2009

Case Reports

View full text Add to dashboard Cite

Aripiprazole (APZ) is a novel antipsychotic agent which does not block dopamine (DA) receptors but is rather a partial DA agonist. Thus, it has been proposed that APZ may not induce tardive dyskinesia (TD), a disfiguring and sometimes disabling and irreversible side effect of neuroleptics. Our patient had Lewy body dementia (LBD) and developed severe worsening of parkinsonism over 1 month of APZ treatment. Within days of discontinuation of APZ dramatic orobuccal dyskinesias emerged. Treatment emergent worsening of parkinsonism improved but orobuccal dyskinesias persisted unchanged until his death 8 months later. Others have reported severe extrapyramidal reactions including neuroleptic malignant syndrome and TD with APZ. APZ has been suggested as a treatment for TD but treatment benefit may reflect "masked" dyskinesia. We conclude that, despite an attractive in vitro profile and promising animal data, APZ can induce serious extrapyramidal side effects, including TD.

show abstract

Section: Discussionmentioning

confidence: 92%

Motor worsening and tardive dyskinesia with aripiprazole in Lewy body dementia

Boylan

Hirsch²

2009

Case Reports

View full text Add to dashboard Cite

show abstract

“…However, only one of the patients had a full and sustained remission of TD after treatment, revealing that aripiprazole might not be equally effective in all psychogeriatric patients. Six other cases of improvement in neuroleptic-induced TD during treatment with aripiprazole have been reported (Duggal 2003;Grant and Baldessarini 2005;Sharma et al 2005;Witschy and Winter 2005;Lykouras et al 2007;Anonymous 2008). Aripiprazole is an atypical antipsychotic drug with a unique mechanism of action: partial agonism at D2 receptors, antagonism at 5-HT2 receptors, and partial agonism at 5-HT1A receptors.…”

Section: Discussionmentioning

confidence: 98%

Treatment of Tardive Dyskinesia with Aripiprazole

et al. 2009

View full text Add to dashboard Cite

Tardive dyskinesia (TD) is a severe and potential irreversible side effect of antipsychotic treatment. Treatment of established TD is often unsuccessful. In this article, we report three cases of psychogeriatric patients who suffered from TD as a side effect of long-term treatment with haloperidol that resolved after switching treatment to aripiprazole. Potential psychopharmacological mechanisms explaining this finding are briefly discussed.

show abstract

“…26 Although most drugs with the potential to cause TD belong to the antipsychotic family of drugs (phenothiazines, thioxanthenes, butyrophenones, etc), other medications for non-psychiatric-related problems, such as metoclopramide, antagonize dopamine receptors and may, therefore, cause TD. Given our current level of understanding of the pathophysiology, we recommend caution treating TD with DRBDs, even the so-called atypical antipsychotics, such as risperidone, 27 amisulpride, 28 quetiapine, 29 or aripiprazole, [30][31][32] as many of these drugs are not truly "atypical" and have been associated with TD. 18,[33][34][35] It is not known why female patients are at a greater risk to develop TD, but it has been reported in several studies.…”

Section: Discussionmentioning

confidence: 99%

Metoclopramide, an Increasingly Recognized Cause of Tardive Dyskinesia

Kenney

Hunter

Davidson

et al. 2008

The Journal of Clinical Pharma

View full text Add to dashboard Cite

T ardive dyskinesia (TD), a hyperkinetic movement disorder causally related to dopamine receptorblocking drug (DRBD) exposure, is a well-recognized iatrogenic disorder in adults 1 and less commonly seen in children and infants. 2,3 Although the literature on TD mainly focuses on patients treated with DRBDs used as antipsychotics, DRBDs are also used to treat a wide array of medical, chiefly gastrointestinal, conditions. 4-6 Although most of the drugs that cause TD are DRBDs that antagonize dopamine D 2 receptors, other classes of drugs have the potential to cause TD, including antidepressants and calcium channel blockers. The reported lifetime prevalence of TD in patients treated with traditional DRBDs has varied greatly, with an average of about 25% of exposed adults. 1,7 Risk factors associated with the development of TD include advanced age, female gender, and, more important, total cumulative drug exposure. [8][9][10][11] We sought to determine which drugs most commonly cause TD in patients referred to our clinic. MATERIALS AND METHODSAfter approval by the institutional review board, a retrospective chart review of 583 charts was performed on patients evaluated for TD in the Parkinson's Disease and Movement Disorders Clinic at Baylor College of Medicine between 1981 and January 2006. We included all patients who met clinical criteria for TD 12 : (1) exhibited a hyperkinetic movement disorder, (2) had a documented exposure to 1 or more DRBDs for at least 3 months before the onset of symptoms, and (3) the hyperkinetic movement disorder persisted for at least 1 month after stopping the offending DRBD. 12 A total of 434 charts were used specifically for this study; 149 charts were excluded because of incorrect diagnostic coding, accidental destruction of charts, and loss to follow-up. We excluded patients with drug-induced parkinsonism. 13 All data related to demographics (age/gender), treatment indication (psychiatric/gastrointestinal/ other), phenomenology (stereotypy/dystonia/chorea/ tic/tremor), and offending agent were captured on case report forms and transferred to a database. RESULTSWe report data on 434 TD patients for whom we have detailed clinical information. Patients, of whom 334 were women (77.0%), had a mean age of 63.8 ± 14.8 years at their initial evaluation. Since its inception, 23 653 movement disorder patients have been evaluated at Baylor College of Medicine, 11 802 of whom were women (50.0%). There was no statistical difference in the proportion of women presenting with a psychiatric treatment indication when compared with those with a gastrointestinal disorder. The majority presented with oro-faciallingual stereotypy (n = 198, 45.6%), dystonia (n = 165, 38.0%), or other stereotypies (n = 159, 36.6%).

show abstract

Improvement in Tardive Dyskinesia with Aripiprazole Use

Cited by 26 publications

References 4 publications

Motor worsening and tardive dyskinesia with aripiprazole in Lewy body dementia

Motor worsening and tardive dyskinesia with aripiprazole in Lewy body dementia

Treatment of Tardive Dyskinesia with Aripiprazole

Metoclopramide, an Increasingly Recognized Cause of Tardive Dyskinesia

Contact Info

Product

Resources

About